Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science, a subsidiary of KetamineOne Capital (NEO: MEDI), this morning announcing its involvement in the latest trial. The contract research organization is set to assist in the process of the trials via facilities in Miami, Florida.
The CRO has been contracted by an unrelated third party to assist with the research of the trial, with KGK set to “develop the protocol and informed consent form” for the third parties institutional review board application for the trial. The trial is set to mark one of the first such trials on ketamine, with the study looking to understand how the compound is related to neuroplasticity.
The study will also focus its efforts on finding data to support the notion that the compound can assist in providing relief from depression, with or without post traumatic stress disorder. The trials themselves are to take place in Florida at medical facilities operated by the third party, with the assistance of KGK Science.
“If the third party and its partner can record sustainable changes in brain electroencephalograms that correlate strongly to patient outcomes, then they could be on their way to making this protocol a new standard of care,” commented KGK’s CEO, Najla Guthrie.
KetamineOne Capital last traded at $0.69 on the Neo Exchange.
FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
